MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SUVEN LIFE SCIENCES LTD. (pharmaceuticals)
- SUVEN LIFE SCIENCES LTD. Financial Data
SUVEN LIFE Fact Sheet (SVNP)
Here is the latest financial fact sheet of SUVEN LIFE. For more details, see the SUVEN LIFE quarterly results and SUVEN LIFE share price and chart. For a sector overview, read our pharmaceuticals sector report.
SUVEN LIFESCIENCES Price History
| % ch | % | 1.7 |
| No. of shares | m | 116.83 |
| % ch week | % | -2.6 |
| % ch 1-mth | % | -8.0 |
| % ch 12-mth | % | 10.4 |
| 52 week H/L | Rs | 337.7/183.3 |
SUVEN LIFESCIENCES Financials
| No. of Mths Year Ending |
12 Mar-14 |
12 Mar-15 |
12 Mar-16 |
12 Mar-17 |
12 Mar-18 |
5-Yr Chart Click to enlarge
|
|---|
| SUVEN LIFESCIENCES EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 83 | 323 | 339 | 229 | 251 | |
| Low | Rs | 22 | 72 | 144 | 151 | 155 | |
| Sales per share (Unadj.) | Rs | 43.7 | 40.9 | 39.2 | 42.7 | 49.1 | |
| Earnings per share (Unadj.) | Rs | 12.3 | 8.5 | 5.6 | 6.9 | 9.7 | |
| Diluted earnings per share | Rs | 12.3 | 9.3 | 6.1 | 7.5 | 10.6 | |
| Cash flow per share (Unadj.) | Rs | 13.1 | 9.5 | 7.0 | 8.5 | 11.4 | |
| Dividends per share (Unadj.) | Rs | 0.50 | 0.60 | 2.00 | 1.00 | 1.50 | |
| Adj. dividends per share | Rs | 0.50 | 0.65 | 2.18 | 1.09 | 1.63 | |
| Dividend yield (eoy) | % | 0.9 | 0.3 | 0.8 | 0.5 | 0.7 | |
| Book value per share (Unadj.) | Rs | 22.6 | 44.3 | 46.8 | 52.4 | 60.3 | |
| Adj. book value per share | Rs | 22.6 | 48.2 | 51.0 | 57.1 | 65.7 | |
| Shares outstanding (eoy) | m | 116.82 | 127.28 | 127.28 | 127.28 | 127.28 | |
| Bonus/Rights/Conversions | - | IS | - | - | - | ||
| Price / Sales ratio | x | 1.2 | 4.8 | 6.2 | 4.4 | 4.1 | |
| Avg P/E ratio | x | 4.3 | 23.1 | 42.8 | 27.7 | 20.9 | |
| P/CF ratio (eoy) | x | 4.0 | 20.8 | 34.4 | 22.2 | 17.8 | |
| Price / Book Value ratio | x | 2.3 | 4.5 | 5.2 | 3.6 | 3.4 | |
| Dividend payout | % | 4.1 | 7.0 | 35.4 | 14.6 | 15.4 | |
| Avg Mkt Cap | Rs m | 6,156 | 25,100 | 30,732 | 24,158 | 25,825 | |
| No. of employees | `000 | NA | 0.9 | 1.0 | 1.0 | 1.1 | |
| Total wages/salary | Rs m | 314 | 365 | 409 | 522 | 613 | |
| Avg. sales/employee | Rs Th | NM | 5,912.1 | 5,236.1 | 5,349.7 | 5,832.6 | |
| Avg. wages/employee | Rs Th | NM | 414.4 | 429.1 | 513.5 | 571.5 | |
| Avg. net profit/employee | Rs Th | NM | 1,234.4 | 753.0 | 858.1 | 1,153.8 | |
| SUVEN LIFESCIENCES INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 5,103 | 5,209 | 4,995 | 5,435 | 6,253 | |
| Other income | Rs m | 30 | 86 | 194 | 211 | 233 | |
| Total revenues | Rs m | 5,133 | 5,294 | 5,189 | 5,646 | 6,485 | |
| Gross profit | Rs m | 2,191 | 1,595 | 1,016 | 1,291 | 1,982 | |
| Depreciation | Rs m | 88 | 118 | 175 | 214 | 213 | |
| Interest | Rs m | 105 | 47 | 59 | 57 | 46 | |
| Profit before tax | Rs m | 2,027 | 1,516 | 976 | 1,231 | 1,955 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 586 | 428 | 257 | 359 | 718 | |
| Profit after tax | Rs m | 1,442 | 1,088 | 718 | 872 | 1,237 | |
| Gross profit margin | % | 42.9 | 30.6 | 20.3 | 23.7 | 31.7 | |
| Effective tax rate | % | 28.9 | 28.2 | 26.4 | 29.2 | 36.7 | |
| Net profit margin | % | 28.2 | 20.9 | 14.4 | 16.0 | 19.8 | |
| SUVEN LIFESCIENCES BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 2,806 | 4,494 | 4,277 | 4,917 | 5,622 | |
| Current liabilities | Rs m | 1,551 | 1,185 | 1,107 | 1,186 | 1,168 | |
| Net working cap to sales | % | 24.6 | 63.5 | 63.5 | 68.6 | 71.2 | |
| Current ratio | x | 1.8 | 3.8 | 3.9 | 4.1 | 4.8 | |
| Inventory Days | Days | 56 | 57 | 61 | 62 | 81 | |
| Debtors Days | Days | 47 | 28 | 39 | 31 | 36 | |
| Net fixed assets | Rs m | 1,921 | 2,790 | 3,126 | 3,154 | 3,325 | |
| Share capital | Rs m | 117 | 127 | 127 | 127 | 127 | |
| "Free" reserves | Rs m | 2,125 | 5,510 | 5,826 | 6,543 | 7,547 | |
| Net worth | Rs m | 2,645 | 5,637 | 5,953 | 6,670 | 7,674 | |
| Long term debt | Rs m | 377 | 594 | 416 | 259 | 14 | |
| Total assets | Rs m | 4,866 | 7,456 | 7,515 | 8,157 | 9,135 | |
| Interest coverage | x | 20.3 | 33.2 | 17.6 | 22.7 | 43.2 | |
| Debt to equity ratio | x | 0.1 | 0.1 | 0.1 | 0 | 0 | |
| Sales to assets ratio | x | 1.0 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Return on assets | % | 31.8 | 15.2 | 10.3 | 11.4 | 14.0 | |
| Return on equity | % | 54.5 | 19.3 | 12.1 | 13.1 | 16.1 | |
| Return on capital | % | 70.6 | 25.1 | 16.2 | 18.6 | 26.0 | |
| Exports to sales | % | 90.1 | 88.1 | 87.5 | 0 | 0 | |
| Imports to sales | % | 9.4 | 11.6 | 12.2 | 0 | 0 | |
| Exports (fob) | Rs m | 4,600 | 4,590 | 4,371 | 0 | 0 | |
| Imports (cif) | Rs m | 482 | 602 | 611 | 0 | 0 | |
| Fx inflow | Rs m | 4,752 | 4,779 | 4,666 | 4,943 | 5,066 | |
| Fx outflow | Rs m | 608 | 855 | 942 | 1,857 | 2,001 | |
| Net fx | Rs m | 4,143 | 3,924 | 3,724 | 3,086 | 3,065 | |
| SUVEN LIFESCIENCES CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 1,212 | 1,429 | 675 | 1,092 | 699 | |
| From Investments | Rs m | -355 | -1,105 | -386 | -3,107 | -6 | |
| From Financial Activity | Rs m | -382 | 1,791 | -681 | -304 | -577 | |
| Net Cashflow | Rs m | 474 | 2,116 | -392 | -2,319 | 116 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| COMP SEC: K. Hanumantha Rao | YEAR OF INC: 1989 | BSE CODE: 530239 | FV (Rs): 1 | DIV YIELD (%): 0.7 |
Read: SUVEN LIFE 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DR. REDDYS LAB CIPLA AJANTA PHARMA GSK PHARMA DISHMAN PHARMA
Compare SUVEN LIFESCIENCES With: DR. REDDYS LAB CIPLA AJANTA PHARMA GSK PHARMA DISHMAN PHARMA
Compare SUVEN LIFESCIENCES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)
Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.
Views on news
SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.
SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)
Aug 14, 2018 | Updated on Aug 14, 2018Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.
Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)
Sep 22, 2017Muted growth in CRAMS segment continues to impact topline.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
A One Stock Crorepati (Profit Hunter)
Jul 4, 2019Do you wish you could become a crorepati in the stock market? Read on...
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)
Jul 5, 2019Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?
More|
| |
TRACK SUVEN LIFESCIENCES
- Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUVEN LIFESCIENCES
SUVEN LIFESCIENCES 8-QTR ANALYSIS
COMPARE SUVEN LIFESCIENCES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.